Lipid Nanoparticles Beyond Vaccines: New Frontiers In Targeted And Personalized Therapeutics

Vaccine-era lipid nanoparticles were built for one or a few doses. Chronic protein replacement, gene editing, and patient-specific cancer vaccines ask for something different: formulations that stay tolerable over repeated administration, remain stable outside the ultra-cold chain, and reach tissues the liver otherwise captures. Drawing on interviews with Cytiva scientists, this ebook examines how the strategy shifts from potency-driven to tolerance-driven design, what a nine-dose mouse study showed about anti-PEG responses, and how formulation choices change where particles go. It also considers lung delivery by nebulization and a spleen-targeting approach tied to in vivo CAR T therapy.

Access the full ebook to explore the data and expert perspectives to see where the field is heading.